1. Home
  2. CLRB vs ASNS Comparison

CLRB vs ASNS Comparison

Compare CLRB & ASNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLRB
  • ASNS
  • Stock Information
  • Founded
  • CLRB 2002
  • ASNS 1998
  • Country
  • CLRB United States
  • ASNS United States
  • Employees
  • CLRB N/A
  • ASNS N/A
  • Industry
  • CLRB Biotechnology: Pharmaceutical Preparations
  • ASNS Telecommunications Equipment
  • Sector
  • CLRB Health Care
  • ASNS Telecommunications
  • Exchange
  • CLRB Nasdaq
  • ASNS Nasdaq
  • Market Cap
  • CLRB 12.8M
  • ASNS 9.8M
  • IPO Year
  • CLRB N/A
  • ASNS 2022
  • Fundamental
  • Price
  • CLRB $0.32
  • ASNS $0.76
  • Analyst Decision
  • CLRB Buy
  • ASNS Strong Buy
  • Analyst Count
  • CLRB 2
  • ASNS 1
  • Target Price
  • CLRB $28.00
  • ASNS $5.00
  • AVG Volume (30 Days)
  • CLRB 1.3M
  • ASNS 156.8K
  • Earning Date
  • CLRB 03-13-2025
  • ASNS 03-25-2025
  • Dividend Yield
  • CLRB N/A
  • ASNS N/A
  • EPS Growth
  • CLRB N/A
  • ASNS N/A
  • EPS
  • CLRB N/A
  • ASNS N/A
  • Revenue
  • CLRB N/A
  • ASNS $7,715,000.00
  • Revenue This Year
  • CLRB N/A
  • ASNS $76.45
  • Revenue Next Year
  • CLRB $208.14
  • ASNS $25.80
  • P/E Ratio
  • CLRB N/A
  • ASNS N/A
  • Revenue Growth
  • CLRB N/A
  • ASNS 8.31
  • 52 Week Low
  • CLRB $0.22
  • ASNS $0.36
  • 52 Week High
  • CLRB $4.17
  • ASNS $4.60
  • Technical
  • Relative Strength Index (RSI)
  • CLRB 51.53
  • ASNS 30.70
  • Support Level
  • CLRB $0.30
  • ASNS $0.66
  • Resistance Level
  • CLRB $0.34
  • ASNS $1.08
  • Average True Range (ATR)
  • CLRB 0.03
  • ASNS 0.07
  • MACD
  • CLRB 0.01
  • ASNS -0.02
  • Stochastic Oscillator
  • CLRB 65.14
  • ASNS 23.15

About CLRB Cellectar Biosciences Inc.

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

About ASNS Actelis Networks Inc.

Actelis Networks Inc is a networking solutions company with a mission to enable communication for Internet of Things, or IoT, projects, deployed over wide areas such as cities, campuses, airports, military bases, roads, and rail. Its networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines to create a cost-effective, secure, and quick-to-deploy network. Its solutions also offer end-to-end network security to protect critical IoT data, utilizing a powerful combination of coding and encryption technologies, applied as required on both new and existing infrastructure within the hybrid-fiber-copper network. The Company operates as one operating segment developing and marketing access broadband equipment for copper and fiber networks.

Share on Social Networks: